Catalent Pharma Solutions, Inc. -- Moody's reviews Catalent's CFR for upgrade after IPO

New York, July 31, 2014 -- Moody's Investors Service placed Catalent Pharma Solutions, Inc.'s ("Catalent") Corporate Family Rating of B2, Probability of Default rating of B2-PD and Senior Unsecured Term loan rating of Caa1 under review for possible upgrade after the company announced its expected pricing of its initial public offering and intended use of the proceeds for debt repayment. At the same time, Moody's placed the Ba3 rating on the senior secured credit facilities under review for downgrade and affirmed the ratings on the senior unsecured notes and senior subordinated. The speculative grade liquidity rating of SGL-2 was affirmed.

Vollständigen Artikel bei Moodys lesen